Literature DB >> 32723699

Comparing the Rule of 5 to Trend-based Analysis for Detecting Glaucoma Progression on OCT.

Atalie C Thompson1, Alessandro A Jammal1, Samuel I Berchuck2, Eduardo B Mariottoni1, Zhichao Wu3, Fabio B Daga1, Nara G Ogata1, Carla N Urata1, Tais Estrela1, Felipe A Medeiros4.   

Abstract

PURPOSE: The rule of 5 is a simple rule for detecting retinal nerve fiber layer (RNFL) change on spectral-domain OCT (SD-OCT), in which a loss of 5 μm of global RNFL on a follow-up test is considered evidence of significant change when compared with the baseline. The rule is based on short-term test-retest variability of SD-OCT and is often used in clinical practice. The purpose of this study was to compare the rule of 5 with trend-based analysis of global RNFL thickness over time for detecting glaucomatous progression.
DESIGN: Prospective cohort. PARTICIPANTS: A total of 300 eyes of 210 glaucoma subjects followed for an average of 5.4±1.5 years with a median of 11 (interquartile range, 7-14) visits.
METHODS: Trend-based analysis was performed by ordinary least-squares (OLS) linear regression of global RNFL thickness over time. For estimation of specificity, false-positives were obtained by assessing for progression on series of randomly permutated follow-up visits for each eye, which removes any systematic trend over time. The specificity of trend-based analysis was matched to that of the rule of 5 to allow meaningful comparison of the "hit rate," or the proportion of glaucoma eyes categorized as progressing at each time point, using the original sequence of visits. MAIN OUTCOME MEASURES: Comparison between hit rates of trend-analysis versus rule of 5 at matched specificity.
RESULTS: After 5 years, the simple rule of 5 identified 37.5% of eyes as progressing at a specificity of 81.1%. At the same specificity, the hit rate for trend-based analysis was significantly greater than that of the rule of 5 (62.9% vs. 37.5%; P < 0.001). If the rule of 5 was required to be repeatable on a consecutive test, specificity improved to 93.4%, but hit rate decreased to 21.0%. At this higher specificity, trend-based analysis still had a significantly greater hit rate than the rule of 5 (47.4% vs. 21.0%, respectively; P < 0.001).
CONCLUSIONS: Trend-based analysis was superior to the simple rule of 5 for identifying progression in glaucoma eyes and should be preferred as a method for longitudinal assessment of global SD-OCT RNFL change over time.
Copyright © 2020 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32723699      PMCID: PMC7704802          DOI: 10.1016/j.ogla.2020.06.005

Source DB:  PubMed          Journal:  Ophthalmol Glaucoma        ISSN: 2589-4196


  33 in total

1.  The structure and function relationship in glaucoma: implications for detection of progression and measurement of rates of change.

Authors:  Felipe A Medeiros; Linda M Zangwill; Christopher Bowd; Kaweh Mansouri; Robert N Weinreb
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-10-05       Impact factor: 4.799

2.  Retinal nerve fiber layer imaging with spectral-domain optical coherence tomography: a prospective analysis of age-related loss.

Authors:  Christopher K S Leung; Marco Yu; Robert N Weinreb; Cong Ye; Shu Liu; Gilda Lai; Dennis S C Lam
Journal:  Ophthalmology       Date:  2012-01-20       Impact factor: 12.079

3.  Performance of the 10-2 and 24-2 Visual Field Tests for Detecting Central Visual Field Abnormalities in Glaucoma.

Authors:  Zhichao Wu; Felipe A Medeiros; Robert N Weinreb; Linda M Zangwill
Journal:  Am J Ophthalmol       Date:  2018-08-10       Impact factor: 5.258

4.  Importance of Normal Aging in Estimating the Rate of Glaucomatous Neuroretinal Rim and Retinal Nerve Fiber Layer Loss.

Authors:  Jayme R Vianna; Vishva M Danthurebandara; Glen P Sharpe; Donna M Hutchison; Anne C Belliveau; Lesya M Shuba; Marcelo T Nicolela; Balwantray C Chauhan
Journal:  Ophthalmology       Date:  2015-10-01       Impact factor: 12.079

5.  The impact of glaucoma on the quality of life of patients in Norway. I. Results from a self-administered questionnaire.

Authors:  T Odberg; J E Jakobsen; S J Hultgren; R Halseide
Journal:  Acta Ophthalmol Scand       Date:  2001-04

6.  Estimating the rate of retinal ganglion cell loss in glaucoma.

Authors:  Felipe A Medeiros; Linda M Zangwill; Douglas R Anderson; Jeffrey M Liebmann; Christopher A Girkin; Ronald S Harwerth; Marie-Josée Fredette; Robert N Weinreb
Journal:  Am J Ophthalmol       Date:  2012-07-27       Impact factor: 5.258

Review 7.  Detecting Structural Progression in Glaucoma with Optical Coherence Tomography.

Authors:  Andrew J Tatham; Felipe A Medeiros
Journal:  Ophthalmology       Date:  2017-12       Impact factor: 12.079

8.  Comparison of Short- And Long-Term Variability in Standard Perimetry and Spectral Domain Optical Coherence Tomography in Glaucoma.

Authors:  Carla N Urata; Eduardo B Mariottoni; Alessandro A Jammal; Nara G Ogata; Atalie C Thompson; Samuel I Berchuck; Tais Estrela; Felipe A Medeiros
Journal:  Am J Ophthalmol       Date:  2019-11-09       Impact factor: 5.258

9.  Visual field progression in glaucoma: estimating the overall significance of deterioration with permutation analyses of pointwise linear regression (PoPLR).

Authors:  Neil O'Leary; Balwantray C Chauhan; Paul H Artes
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-10-01       Impact factor: 4.799

10.  The Relative Odds of Progressing by Structural and Functional Tests in Glaucoma.

Authors:  Ricardo Y Abe; Alberto Diniz-Filho; Linda M Zangwill; Carolina P B Gracitelli; Amir H Marvasti; Robert N Weinreb; Saif Baig; Felipe A Medeiros
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-07-01       Impact factor: 4.799

View more
  1 in total

1.  Prediction of visual field defects from macular optical coherence tomography in glaucoma using cluster analysis.

Authors:  Janelle Tong; David Alonso-Caneiro; Michael Kalloniatis; Barbara Zangerl
Journal:  Ophthalmic Physiol Opt       Date:  2022-05-22       Impact factor: 3.992

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.